Verrica Pharmaceuticals Inc. (VRCA) Misses Q2 EPS by 8c
Tweet
Share
E-mailGet Alerts VRCA Hot Sheet
Join SI Premium – FREE
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) reported Q2 EPS of ($0.48), $0.08 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $5.9 million versus the consensus estimate of $5.9 million.
For earnings history and earnings-related data on Verrica Pharmaceuticals Inc. (VRCA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bessent: We Make A Market Buying Older Bonds
- NY Fed survey shows rising unemployment fears, mixed financial outlook
- Mizuho Defends Sarepta Therapeutics (SRPT)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
